vs
Side-by-side financial comparison of BayCom Corp (BCML) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
BayCom Corp is the larger business by last-quarter revenue ($25.9M vs $16.1M, roughly 1.6× Journey Medical Corp). BayCom Corp runs the higher net margin — 26.5% vs -7.8%, a 34.3% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 9.4%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 2.9%).
BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
BCML vs DERM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $16.1M |
| Net Profit | $6.9M | $-1.2M |
| Gross Margin | — | — |
| Operating Margin | 36.6% | -2.8% |
| Net Margin | 26.5% | -7.8% |
| Revenue YoY | 9.4% | 27.3% |
| Net Profit YoY | 12.1% | -182.0% |
| EPS (diluted) | $0.63 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.9M | $16.1M | ||
| Q3 25 | $25.7M | $17.0M | ||
| Q2 25 | $24.7M | $15.0M | ||
| Q1 25 | $24.3M | $13.1M | ||
| Q4 24 | $23.7M | $12.6M | ||
| Q3 24 | $25.6M | $14.6M | ||
| Q2 24 | $23.8M | $14.9M | ||
| Q1 24 | $24.5M | $13.0M |
| Q4 25 | $6.9M | $-1.2M | ||
| Q3 25 | $5.0M | $-2.3M | ||
| Q2 25 | $6.4M | $-3.8M | ||
| Q1 25 | $5.7M | $-4.1M | ||
| Q4 24 | $6.1M | $1.5M | ||
| Q3 24 | $6.0M | $-2.4M | ||
| Q2 24 | $5.6M | $-3.4M | ||
| Q1 24 | $5.9M | $-10.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 82.3% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 56.0% | ||
| Q1 24 | — | 47.7% |
| Q4 25 | 36.6% | -2.8% | ||
| Q3 25 | 26.3% | -9.0% | ||
| Q2 25 | 35.3% | -19.2% | ||
| Q1 25 | 31.6% | -25.3% | ||
| Q4 24 | 34.2% | 17.7% | ||
| Q3 24 | 32.4% | -19.8% | ||
| Q2 24 | 31.9% | -19.7% | ||
| Q1 24 | 33.3% | -77.4% |
| Q4 25 | 26.5% | -7.8% | ||
| Q3 25 | 19.5% | -13.6% | ||
| Q2 25 | 25.8% | -25.3% | ||
| Q1 25 | 23.4% | -31.0% | ||
| Q4 24 | 25.9% | 12.1% | ||
| Q3 24 | 23.5% | -16.3% | ||
| Q2 24 | 23.6% | -22.6% | ||
| Q1 24 | 24.0% | -80.1% |
| Q4 25 | $0.63 | $-0.04 | ||
| Q3 25 | $0.46 | $-0.09 | ||
| Q2 25 | $0.58 | $-0.16 | ||
| Q1 25 | $0.51 | $-0.18 | ||
| Q4 24 | $0.55 | $0.10 | ||
| Q3 24 | $0.54 | $-0.12 | ||
| Q2 24 | $0.50 | $-0.17 | ||
| Q1 24 | $0.51 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $24.1M |
| Total DebtLower is stronger | — | $25.3M |
| Stockholders' EquityBook value | $338.6M | $31.9M |
| Total Assets | $2.6B | $94.6M |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $24.1M | ||
| Q3 25 | — | $24.9M | ||
| Q2 25 | — | $20.3M | ||
| Q1 25 | — | $21.1M | ||
| Q4 24 | — | $20.3M | ||
| Q3 24 | — | $22.5M | ||
| Q2 24 | — | $23.9M | ||
| Q1 24 | — | $24.1M |
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | $338.6M | $31.9M | ||
| Q3 25 | $334.3M | $25.9M | ||
| Q2 25 | $330.6M | $19.2M | ||
| Q1 25 | $329.3M | $21.5M | ||
| Q4 24 | $324.4M | $20.1M | ||
| Q3 24 | $321.7M | $10.9M | ||
| Q2 24 | $315.3M | $11.3M | ||
| Q1 24 | $314.2M | $13.0M |
| Q4 25 | $2.6B | $94.6M | ||
| Q3 25 | $2.6B | $85.2M | ||
| Q2 25 | $2.6B | $81.2M | ||
| Q1 25 | $2.6B | $85.0M | ||
| Q4 24 | $2.7B | $80.2M | ||
| Q3 24 | $2.6B | $64.0M | ||
| Q2 24 | $2.6B | $65.2M | ||
| Q1 24 | $2.6B | $66.6M |
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.8M | $-6.3M |
| Free Cash FlowOCF − Capex | $30.1M | — |
| FCF MarginFCF / Revenue | 116.2% | — |
| Capex IntensityCapex / Revenue | 6.7% | — |
| Cash ConversionOCF / Net Profit | 4.64× | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | $-6.3M | ||
| Q3 25 | $7.3M | $-2.4M | ||
| Q2 25 | $6.4M | $-942.0K | ||
| Q1 25 | $9.3M | $-2.8M | ||
| Q4 24 | $30.4M | $2.2M | ||
| Q3 24 | $9.6M | $-1.2M | ||
| Q2 24 | $7.7M | $-5.2M | ||
| Q1 24 | $5.1M | $-5.0M |
| Q4 25 | $30.1M | — | ||
| Q3 25 | $6.2M | — | ||
| Q2 25 | $5.6M | — | ||
| Q1 25 | $9.1M | — | ||
| Q4 24 | $28.7M | — | ||
| Q3 24 | $9.4M | — | ||
| Q2 24 | $7.4M | — | ||
| Q1 24 | $3.9M | — |
| Q4 25 | 116.2% | — | ||
| Q3 25 | 24.3% | — | ||
| Q2 25 | 22.8% | — | ||
| Q1 25 | 37.6% | — | ||
| Q4 24 | 121.1% | — | ||
| Q3 24 | 36.6% | — | ||
| Q2 24 | 31.2% | — | ||
| Q1 24 | 16.1% | — |
| Q4 25 | 6.7% | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 3.0% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 7.2% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 4.7% | — |
| Q4 25 | 4.64× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 4.96× | 1.46× | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 0.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCML
Segment breakdown not available.
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
